Retatrutide — - 30mg

Retatrutide (LY3437943) is a novel, investigational peptide agonist engineered for advanced metabolic research. It is distinguished within the field of peptide therapeutics by its unique tri-agonist mechanism, simultaneously targeting three key receptors involved in glucose and energy homeostasis: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). This triple-hormone-receptor agonist, often referred to as a 'GGG' agonist, represents a significant evolution from single-agonist (e.g., semaglutide) and dual-agonist (e.g., tirzepatide) compounds.

The structure of Retatrutide is based on a GIP peptide backbone, modified to confer potent and balanced activity at all three target receptors. It is a 39-amino acid linear peptide that has been further modified by the attachment of a C20 fatty diacid moiety via a linker to the lysine residue at position 20. This lipidation strategy significantly extends the peptide's circulating half-life by promoting reversible binding to serum albumin, thereby reducing renal clearance and enzymatic degradation. This modification makes it suitable for less frequent administration in longitudinal preclinical research models.

Retatrutide's emergence is a direct result of research aimed at recapitulating the profound metabolic benefits observed after bariatric surgery, which is known to elevate circulating levels of multiple gut hormones simultaneously. The hypothesis underlying its design is that synergistic activation of GLP-1R, GIPR, and GCGR can produce more substantial effects on weight reduction, glycemic control, and energy expenditure than targeting one or two of these pathways alone. Its investigation in laboratory settings focuses on elucidating the complex interplay between these signaling systems and their potential to address multifaceted metabolic disorders like obesity, type 2 diabetes mellitus (T2DM), and non-alcoholic steatohepatitis (NASH). For researchers, Retatrutide provides a powerful tool to explore the integrated physiology of incretin and glucagon signaling pathways.

Nexa Peptides supplies Retatrutide exclusively for laboratory research purposes. This product is not intended for human or veterinary use. Its application is strictly limited to in vitro and in vivo studies conducted by qualified scientific professionals in a controlled research environment. Every batch is rigorously tested to ensure the highest purity and quality for reproducible experimental outcomes.

Retatrutide's mechanism of action is defined by its function as a single-molecule tri-agonist with engineered affinity for the GLP-1, GIP, and glucagon receptors. These are all Class B G-protein coupled receptors (GPCRs) that primarily signal through the Gαs subunit, leading to the activation of adenylyl cyclase and a subsequent increase in intracellular cyclic adenosine monophosphate (cAMP) levels. The activation of Protein Kinase A (PKA) and other downstream effectors like Exchange Protein Activated by cAMP (Epac) mediates the majority of the cellular responses. The novelty of Retatrutide lies in the integrated physiological output resulting from the simultaneous engagement of these three distinct but complementary pathways.

GLP-1 Receptor (GLP-1R) Agonism: Activation of GLP-1R in pancreatic β-cells enhances glucose-dependent insulin secretion, a primary mechanism for improving glycemic control. In pancreatic α-cells, it suppresses the secretion of glucagon, particularly in hyperglycemic states. Beyond the pancreas, GLP-1R agonism delays gastric emptying and acts on central nervous system pathways, including those in the hypothalamus and hindbrain, to promote satiety and reduce food intake. This central action is a key contributor to the weight-reducing effects observed in preclinical models.

Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR) Agonism: GIP is a potent incretin hormone that also stimulates glucose-dependent insulin secretion from pancreatic β-cells. Its co-activation with GLP-1R may produce synergistic effects on insulin release. Furthermore, GIPR is expressed in adipose tissue, where its activation is thought to enhance lipid metabolism and storage, potentially improving metabolic flexibility. In the central nervous system, GIPR signaling is also being investigated for its role in appetite regulation, complementing the effects of GLP-1R activation.

Glucagon Receptor (GCGR) Agonism: The inclusion of GCGR agonism is a counterintuitive yet critical component of Retatrutide's design. While glucagon is traditionally known to raise blood glucose levels by stimulating hepatic gluconeogenesis and glycogenolysis, its chronic activation in the context of potent incretin agonism has different effects. GCGR activation in the liver increases energy expenditure, promotes fatty acid oxidation, and reduces hepatic lipid accumulation (steatosis). It is hypothesized that the potent insulinotropic effects of the GLP-1R and GIPR components effectively counteract the potential hyperglycemic action of glucagon, allowing the beneficial energy expenditure and lipolytic effects to dominate. This hepatic action is of particular interest in research models of non-alcoholic fatty liver disease (NAFLD).

The integrated mechanism of Retatrutide is therefore a complex synergy. The GLP-1R and GIPR components provide robust glycemic control and appetite suppression, while the GCGR component adds a distinct mechanism for increasing energy expenditure and reducing hepatic and systemic adiposity. This multi-pronged approach allows researchers to investigate a powerful, combined physiological response that is not achievable with single or dual-agonist peptides, providing a unique tool for studying the fundamental biology of metabolic regulation.

Retatrutide is a subject of intensive investigation in multiple areas of metabolic research, primarily utilizing preclinical in vitro and in vivo models. Its unique tri-agonist profile makes it a valuable tool for exploring complex physiological questions that cannot be addressed by peptides with narrower receptor specificity.

Obesity and Weight Management Research: The most prominent application of Retatrutide in research is the study of obesity. In diet-induced obesity (DIO) animal models, such as mice and rats, investigations have focused on its profound effects on body weight reduction. Research studies document its impact on both fat mass and lean mass, food intake, and energy expenditure. Studies aim to differentiate the contributions of central appetite suppression (via GLP-1R and GIPR) versus increased metabolic rate (via GCGR) to the overall weight loss effect. Comparative studies against dual or single agonists are often performed to establish the potential additive or synergistic benefits of the tri-agonist mechanism in achieving and maintaining a lower body weight.

Type 2 Diabetes Mellitus (T2DM) Research: In preclinical models of T2DM, such as the db/db mouse or Zucker diabetic fatty (ZDF) rat, Retatrutide is investigated for its potent glycemic control properties. Research focuses on its ability to lower blood glucose, reduce HbA1c levels, and improve insulin sensitivity. Studies analyze its effects on pancreatic β-cell function and mass, glucose-stimulated insulin secretion, and the suppression of inappropriate glucagon release. The interplay between the potent incretin effects and the GCGR-mediated metabolic actions is a key area of inquiry.

Non-alcoholic Fatty Liver Disease (NAFLD) and Steatohepatitis (NASH) Research: Retatrutide is of significant interest in the study of NAFLD and its progressive form, NASH. The GCGR agonism component is hypothesized to directly target the hepatic pathophysiology of these conditions. In animal models of NAFLD/NASH, research applications include assessing Retatrutide's ability to reduce hepatic steatosis (liver fat content), mitigate liver inflammation (hepatitis), and prevent or reverse hepatic fibrosis. Researchers use histological analysis and biochemical markers of liver injury (e.g., ALT, AST) to quantify its effects, providing insights into the role of glucagon signaling in liver health.

Cardiometabolic Research: Beyond primary endpoints, Retatrutide is studied for its effects on broader cardiometabolic health markers in relevant animal models. These investigations explore its impact on lipid profiles (triglycerides, cholesterol), blood pressure, and markers of systemic inflammation. Such studies aim to understand the downstream consequences of substantial weight loss and improved glycemic control on the cardiovascular system, providing a more holistic view of its potential metabolic effects in a research context. All applications of Retatrutide are strictly for laboratory-based research and are not for therapeutic or human use.